Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ELIEM THERAPEUTICS, INC.

(ELYM)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 03-10-2022
3.090 USD   -4.33%
16/08Eliem Therapeutics, Inc. : SVB Securities LLC ontvangt een koopadvies
MM
15/08Eliem Therapeutics, Inc. Rapporteert Winstresultaten voor het Tweede Kwartaal en de Zes Maanden Geëindigd op 30 Juni, 2022
CI
02/08Sector-update: Aandelen in de gezondheidszorg verzwakken in een woelige sessie
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op ELIEM THERAPEUTICS, INC.
15/08Eliem Therapeutics : Investor Presentation – August 2022
15/08Eliem Therapeutics : Reports Second Quarter Financial and Business Highlights - Form 8-K
15/08ELIEM THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Results and..
15/08Eliem Therapeutics Reports Second Quarter Financial and Business Highlights
15/08Eliem Therapeutics Reports Second Quarter Financial and Business Highlights
15/08Eliem Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months..
02/08Sector Update: Health Care Stocks Weaken in Choppy Session
02/08Sector Update: Health Care Stocks Starting to Strengthen in Tuesday Tradin..
02/08Eliem Therapeutics to Discontinue ETX-810 Program for Treatment of Lumbosacral Radicula..
02/08Wall Street Falters Pre-Bell as Pelosi's Expected Taiwan Visit Fuels Geopolitical Uncer..
02/08Top Premarket Decliners
02/08Eliem Therapeutics Provides ETX-810 Program Update
02/08Eliem Therapeutics Provides ETX-810 Program Update
02/08Eliem Therapeutics, Inc. Provides ETX-810 Program Update
21/07Eliem Therapeutics : LSRP Investor Event Presentation
18/07Eliem Therapeutics, Inc. : Other Events (form 8-K)
18/07Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatm..
18/07Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatm..
18/07Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatm..
07/07Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022
27/06Eliem Therapeutics, Inc. Announces Last Patient Completed Dosing in Phase 2A Study of E..
27/06Eliem Therapeutics Completes Dosing of Last Patient in Sciatica Treatment Trial
27/06Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810..
27/06Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
24/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from R..
20/06Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from S..
24/05Eliem Therapeutics, Inc. : Submission of Matters to a Vote of Security Holders (form 8-K)
16/05ELIEM THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Results and..
16/05Eliem Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
16/05Eliem Therapeutics Reports First Quarter Financial and Business Highlights
16/05Eliem Therapeutics Reports First Quarter Financial and Business Highlights
25/04Eliem Therapeutics, Inc. : Other Events (form 8-K)
25/04Sector Update: Health Care Stocks Eke Out Gains Late in Monday Trading
25/04Top Midday Decliners
25/04Sector Update: Health Care Stocks Face Pressure in Midday Activity Monday
25/04Wall Street Set to Extend Selloff on Aggressive Fed Tightening Concerns
25/04Sector Update: Health Care Stocks Mixed Premarket Monday
25/04Sector Update: Health Care
25/04Top Premarket Decliners
25/04Eliem Therapeutics' Phase 2a Trial of ETX-810 Fails to Meet Primary Efficacy Goal in Di..
25/04Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs
25/04Eliem Therapeutics Reports Results from its Phase 2A Clinical Trial Investigating ETX-8..
05/04Eliem Therapeutics Appoints Susan Franks as Senior Vice President and Head of Regulator..
05/04Eliem Therapeutics, Inc. Appoints Susan Franks as Senior Vice President and Head of Reg..
29/03Eliem Therapeutics : Investor Presentation dated March 28, 2022 - Form 8-K
29/03Eliem Therapeutics, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
21/03Eliem Therapeutics to Present at Stifel's 2022 CNS Days
07/03Eliem Therapeutics Q4 Loss Narrows; Sees Enough Funds to Run Through Late 2023
07/03Eliem Therapeutics : Reports Fourth Quarter and Year-End Financial and Business Highlights..
07/03Eliem Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December..
07/03Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlight..
07/03ELIEM THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
07/03Eliem Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, ..
11/02Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conferen..
07/02Eliem Therapeutics Host Virtual Investor Event Featuring Opinion Leaders in Chronic Pai..
06/02Certain Common Stock of Eliem Therapeutics, Inc. are subject to a Lock-Up Agreement End..
06/02Certain Stock Options of Eliem Therapeutics, Inc. are subject to a Lock-Up Agreement En..
31/01Eliem Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
18/01Eliem Therapeutics, Inc. : Results of Operations and Financial Condition, Other Events (fo..
18/01Eliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term Miles..
2021Eliem Therapeutics, Inc.(NasdaqGM:ELYM) added to S&P G..
2021Eliem Therapeutics, Inc. : Other Events (form 8-K)
2021Eliem Therapeutics, Inc. Announces Departure of Amy Chappell as Chief Medical Officer E..
2021Eliem Therapeutics Reports Third Quarter Financial and Business Highlights - Form 8-K
2021Eliem Therapeutics, Inc. : Results of Operations and Financial Condition, Regulation FD Di..
2021ELIEM THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Results and..
2021Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
2021Eliem Therapeutics to Participate at Four Upcoming Investor Conferences
2021Eliem Therapeutics, Inc.(NasdaqGM:ELYM) added to S&P T..
2021Eliem Therapeutics' : Q2 Net Loss Widens Over Year-Ago Levels
2021Eliem Therapeutics : Reports Second Quarter Financial Results
2021Eliem Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Seco..
2021Eliem Therapeutics : Management's Discussion and Analysis of Financial Results and Operati..
2021Eliem Therapeutics : Closes IPO; Raises $92 Million in Gross Proceeds
2021Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full o..
2021Eliem Therapeutics, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year..
2021Eliem Therapeutics, Inc.(NasdaqGM:ELYM) added to NASDA..
2021Eliem Therapeutics : Rallies in Nasdaq Debut After Pricing Upsized IP..
2021Eliem Therapeutics : Prices IPO at $12.50/Share
2021Eliem Therapeutics Announces Pricing of Initial Public Offering
2021Eliem Therapeutics, Inc. has completed an IPO in the amount of $80 million.
2021Eliem Therapeutics, Inc. has filed an IPO in the amount of $80 million.
2021Eliem Therapeutics, Inc. announced that it has received $59.999987 million in funding f..
2021Eliem Therapeutics, Inc. announced that it expects to receive $59.999987 million in fun..
Volgende evenement op ELIEM THERAPEUTICS, INC.